



Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17

RICHMOND, Calif., Nov 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced that it will present at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, at 2:10 p.m. Eastern Standard Time. A live audio webcast and replay of the presentation will be available on the Transcept investor webpage at www.transcept.com.

About Transcept

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience. The most advanced Transcept product candidate is *Intermezzo*(R) (zolpidem tartrate sublingual tablet), for which a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in September 2008 seeking approval as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. In October 2009, Transcept received a Complete Response Letter from the FDA on the *Intermezzo*(R) NDA and is working to respond to issues raised in the letter. Transcept and Purdue Pharmaceutical Products, L.P. have entered into a collaboration agreement for the development and commercialization of *Intermezzo*(R) in the United States. For further information, please visit the company's website at: www.transcept.com.

Contact:

Transcept Pharmaceuticals, Inc.
Greg Mann
Director, Corporate Communications
(510) 215-3567
gmann@transcept.com

SOURCE Transcept Pharmaceuticals, Inc.

<http://www.transcept.com>

Copyright (C) 2009 PR Newswire. All rights reserved